JAMA Network
About The Study: In this open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization through month 54. These findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
